Literatur zum CME-Artikel Cannabinoide in der Schmerzmedizin

  1. Beaulieu P, Boulanger A, Desroches J, Clark AJ (2016) Medical cannabis: considerations for the anesthesiologist and pain physician. Can J Anesth 63:608–624
  2. Rätsch C (1998) Hanf als Heilmittel. AT Verlag, Aarau, S 10–121
  3. Most GF (1843) Encyklopädie der gesamten Volksmedicin, oder Lexikon der vorzüglichsten und wirksamsten Haus- und Volksarzneimittel aller Länder. Brockhaus, Leipzig
  4. Dixon WE (1899) The pharmacology of Cannabis indica. BMJ 2:1354–1357
  5. Ransom JJ (1999) “Anslingerian” politics: the history of anti-marijuana sentiment in federal law and how Harry Anslinger’s anti-marijuana politics continue to prevent the FDA and other medical experts from studying marijuana’s medical utility. Food and Drug Law. http://​nrs.​harvard.​edu/​urn-3:​HUL.​InstRepos:​8965561. Zugegriffen: 17. Febr. 2018
  6. Mechoulam R, Shvo Y (1963) The structure of cannabidiol. Tetrahedron 19:2073–2078
  7. Gaoni Y, Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646–1647
  8. Maccarrone M, Bab I, Biro T, Cabral GA, Dey SK, DiMarzo V et al (2015) Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 36(5):277–296
  9. McPartland JM, Guy GW, DiMarzo V (2014) Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS ONE 9(3):e89566
  10. Paunescu H, Coman OA, Coman L, Ghita I, Georgescu SR, Draghia F, Fulga I (2011) Cannabinoid system and cyclooxygenases inhibitors. J Med Life 4(1):11–20
  11. Berger WT, Ralph BP, Kaczocha M, Sun J, Balius TE, Rizzo RC et al (2012) Targeting fatty acid binding protein (FABP) anandamide transporters – a novel strategy for development of anti-inflammatory and anti-nociceptive drugs. PLoS ONE 7(12):e50968
  12. Deutsch DG (2016) A personal retrospective: elevating anandamide (AEA) by targeting fatty acid amide hydrolase (FAAH) and the fatty acid binding proteins (FABPs). Front Pharmacol 7:370
  13. Maejima T, Ohno-shosaku T, Kano M (2001) Endogenous cannabinoid as a retrograde messenger from postsynaptic neurons to presynaptic terminals. Neurosci Res 40:205–210
  14. Mendiguren A, Aostri E, Pineda J (2018) Regulation of noradrenergic and serotonergic systems by cannabinoids: relevance to cannabinoid-induced effects. Life Sci 192:115–127
  15. Piazza PV, Cota D, Marsicano G (2017) The CB1 receptor as the cornerstone of exostasis. Neuron 93(6):1252–1274
  16. Russo EB (2016) Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndroms. Cannabis Cannabinoid Res 1(1):154–165
  17. Karst M, Wippermann S, Ahrens J (2010) Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 70(18):2409–2438
  18. Lötsch J, Weyer-Menkhoff I, Tegeder I (2017) Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings. Eur J Pain. https://​doi.​org/​10.​1002/​ejp.​1148
  19. Agarwal N, Pacher P, Tegeder I et al (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10:870–879
  20. Jhaveri MD, Sagar DR, Elmes SJR, Kendall DA, Chapman V (2007) Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain. Mol Neurobiol 36:26–35
  21. Wotherspoon GA, Fox P, McIntyre S et al (2005) Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 35:235–245
  22. Zurier RB, Burstein SH (2016) Cannabinoids, inflammation, and fibrosis (2016). FASEB J 30(11):3682–3689
  23. Ibrahim MM, Porreca F, Lai J et al (2005) CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 102:3093–3098
  24. Hohmann AG, Suplita RL, Bolton NM et al (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435:1108–1112
  25. Carlino E, Benedetti F (2016) Different contexts, different pains, different experiences. Neuroscience 338:19–26
  26. Morena M, Patel S, Bains JS, Hill MN (2015) Neurobiological interactions between stress and the endocannabinod system. Neuropsychopharmacology 41(1):80–102
  27. Hill MN, Lee FS (2016) Endocannabinoids and stress resilience: is deficiency sufficient to promote vulnerability? Biol Psychiatry 79(10):792–793
  28. Karhson DS, Hardan AY, Parker KJ (2016) Endocannabinoid signaling in social functioning: an RDoC perspective. Transl Psychiatry 6(9):e905
  29. Akerblom S, Perrin S, Rivano Fischer M, McCracken LM (2017) The impact of PTSD on functioning in patients seeking treatment for chronic pain and validation of the posttraumatic diagnostic scale. Int J Behav Med 24(2):249–259
  30. Marsicano G, Wotjak CT, Azad SC et al (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530–534
  31. Fattore L, Melis M, Fadda P, Pistis M, Fratta W (2010) The endocannabinoid system and nondrug rewarding behaviors. Exp Neurol 224(1):23–36
  32. Walker JM, Huang SM, Strangman NM et al (1999) Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A 96:12198–12203
  33. Vachon-Presseau E, Centeno MV, Ren W, Berger SE, Tetreault P, Ghantous M et al (2016) The emotional brain as a predictor and amplifier of chronic pain. J Dent Res 95(6):605–612
  34. Valverde O, Ledent C, Beslot F et al (2000) Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. Eur J Neurosci 12:533–539
  35. Cichewicz DL (2004) Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74:1317–1324
  36. Smith PA, Selley DE, Sim-Selley LJ, Welch SP (2007) Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol 571:129–137
  37. Nielsen S, Sabioni P, Trigo JM, Ware MA, Betz-Stablein BD, Murnion B et al (2017) Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis. Neuropsychopharmacology 42(9):1752–1765
  38. Piper BJ, DeKeuster RM, Beals ML, Cobb CM, Burchman CA, Perkinson L et al (2017) Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol (Oxford) 31(5):569–575
  39. Lee MC, Ploner M, Wiech K, Bingel U, Wanigasekera V, Brooks J, Menon DK, Tracey I (2013) Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain 154:124–134
  40. National Academies of Sciences, Engineering, and Medicine (2017) The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. The National Academies Press, Washington, DC, S 1–487
  41. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV et al (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313(24):2456–2473
  42. Aviram J, Samuelly-Leichtag G (2017) Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician 20(6):E755–E796
  43. Petzke F, Enax-Krumova EK, Häuser W (2016) Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: a systematic review of randomized controlled studies. Schmerz 30(1):62–88
  44. Meng H, Johnston B, Englesakis M, Moulin DE, Bhatia A (2017) Selective cannabinoids for chronic neuropathic pain: a systematic review and meta-analysis. Anesth Analg 125(5):1638–1652
  45. Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W (2018) Cannabis-based medicines for chronic neuropathic pain in adults (Review). Cochrane Database Syst Rev. https://​doi.​org/​10.​1002/​14651858.​CD01282.​pub2
  46. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A et al (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomized placebo-controlled trial. Lancet 362(9395):1517–1526
  47. Grau-Lopez L, Sierra S, Martinez-Caceres E, Ramo-Tello C (2011) Analysis of the pain in multiple sclerosis patients. Neurologia 26(4):208–213
  48. Ferraro D, Plantone D, Morselli F, Dallari G, Simone AM, Vitetta F et al (2018) Systematic assessment and characterization of chronic pain in multiple sclerosis patients. Neurol Sci 39:445–453
  49. Scherder R, Kant N, Wolf ET, Pijnenburg B, Scherder EJ (2018) Psychiatric and physical comorbidities and pain in patients with multiple sclerosis. J Pain Res 11:325–334
  50. Andreae MH, Carter GM, Shaparin N, Suslov K, Ellis RJ, Ware MA et al (2015) Inhaled cannabis for chronic neuropahic pain: a meta-analysis of individual patient data. J Pain 16(12):1221–1232
  51. Häuser W, Fitzcharles MA, Radbruch L, Petzke F (2017) Cannabinoids in pain management and palliative medicine – an overview of systematic reviews and prospective observational studies. Dtsch Arztebl Int 114(38):627–634
  52. Karst M, Passie T (2018) Considerable heterogeneity. Dtsch Arztebl Int 115(9):143
  53. Fitzcharles MA, Baerwald C, Ablin J, Häuser W (2016) Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials. Schmerz 30(1):47–61
  54. Mu A, Weinberg E, Moulin DE, Clarke H (2017) Pharmacologic management of chronic pain. Can Fam Physician 63(11):844–852
  55. Gruccu G, Truini A (2017) A review of neuropathic pain: from guidelines to clinical practice. Pain Ther 6(Suppl 1):S35–S42
  56. La Porta C, Bura SA, Llorente-Onaindia J, Pastor A, Navarrete F, Garcia-Gutierrez MS et al (2015) Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain. Pain 156(10):2001–2012
  57. Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH (2012) Mitigation of post-traumatic stress symptoms by cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal 4(7–8):649–659
  58. Steenkamp MM, Blessing EM, Galatzer-Levy IR, Hollahan LC, Anderson WT (2017) Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: a literature review. Depress Anxiety 34(3):207–216
  59. Lochte BC, Beletsky A, Samuel NK, Grant I (2017) The use of cannabis for headache disorders. Cannabis Cannabinoid Res 2(1):61–71
  60. Hasenoehrl C, Storr M, Schicho R (2017) Cannabinoids for treating inflammatory bowel disease: where are we and where do we go? Expert Rev Gastroenterol Hepatol 11(4):329–337
  61. Koppel BS, Brust JCM, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D (2014) Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders. Neurology 82:1556–1563
  62. Grotenhermen F, Häußermann K (2017) Cannabis. Verordnungshilfe für Ärzte. Wissenschaftliche Verlagsgesellschaft, Stuttgart
  63. https://​www.​arbeitsgemeinsch​aft-cannabis-medizin.​de/​2017/​12/​28/​_​_​trashed-2/​. letzte Änderung 20.02.2018, Zugegriffen: 22. Febr. 2018
  64. https://​dacnrf.​pharmazeutische-zeitung.​de/​index.​php. Zugegriffen: 11. Febr. 2018
  65. Russo EB (2011) Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163(7):1344–1364
  66. Tashkin DP (2013) Effects of marijuana smoking on the lung. Ann Am Thorac Soc 10(3):239–247
  67. Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT (2013) An open-label extension study to investigate the long-term safety and tolerability of the THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage 46:207–218
  68. Huggins JP, Smart TS, Langman S, Taylor L, Young T (2012) An efficient randomized, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153(9):1837–1846
  69. Benson N, Metelkin E, Demin O, Li GL, Nichols D, van der Graaf PH (2014) A systems pharmacology perspective on the clinical development of fatty acid amide hydrolase inhibitors for pain. CPT Pharmacometrics Syst Pharmacol 3:e91
  70. Mallet C, Dubray C, Duale C (2016) FAAH inhibitors in the limelight, but regrettably. Int J Clin Pharmacol Ther 54(7):498–501
  71. Van Esbroeck ACM, Janssen APA, Cognetta AB 3rd, Ogasawara D, Shpak G, van der Kroeg M et al (2017) Acitivity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science 356(6342):1084–1087
  72. https://​clinicaltrials.​gov/​ct2/​show/​NCT03058562?​cond=​Tourette+Syndrom​e&​cntry=​DE&​rank=​1. Zugegriffen: 11. Febr. 2018
  73. Karst M, Wippermann S (2009) Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective. Expert Opin Investig Drugs 18(2):125–133
  74. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U (2003) Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 290(13):1757–1762
  75. Salim K, Schneider U, Burstein S, Hoy L, Karst M (2005) Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology 48(8):1164–1171
  76. https://​www.​corbuspharma.​com. Zugegriffen: 11. Febr. 2018
  77. https://​clinicaltrials.​gov/​ct2/​results?​cond=​&​term=​Palmitoylethanol​amide&​cntry=​&​state=​&​city=​&​dist=​. Zugegriffen: 17. Febr. 2018
  78. Keppel Hesselink JM (2012) New targets in pain, non-neuronal cells, and the role of palmitoylethanolamide. Open Pain J 5:12–23
  79. Karst M (2012) Chronische Schmerzen: Behandlung mit Palmitoylethanolamin. J Club Schmerzmed 2:96
  80. Zhornitsky S, Potvin S (2012) Cannabidiol in humans – the quest for therapeutic targets. Pharmaceuticals 5:529–552
  81. Häußermann K, Wagner U (2017) Cannabidiol: der “rising star” unter den Cannabinoiden? Pharmakon 5(2):123–128
  82. Rukwied R, Watkinson A, McGlone F, Dvorak M (2003) Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 102(3):283–288
  83. Mounessa JS, Siegel JA, Dunnick CA, Dellavalle RP (2017) The role of cannabinoids in dermatology. J Am Acad Dermatol 77(1):188–190
  84. Phan NQ, Siepmann D, Gralow I, Ständer S (2010) Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. J Dtsch Dermatol Ges 8(2):88–91

Artikel teilen

Kommentare (0)

Kommentar schreiben

Die Meinung und Diskussion unserer Nutzer ist ausdrücklich erwünscht. Bitte achten Sie im Sinne einer angenehmen Kommunikation auf unsere Netiquette und Nutzungsbedingungen. Vielen Dank!

* Pflichtfeld

Das PTA Magazin

DAS PTA MAGAZIN wendet sich an das Fachpersonal in der öffentlichen Apotheke, wobei die Zeitschrift insbesondere auf das berufliche Informationsbedürfnis der Pharmazeutisch-Technischen Assistentin eingeht.


Springer Medizin

Springermedizin.de ist das Fortbildungs- und Informationsportal für Ärzte und Gesundheitsberufe, das für Qualität, Aktualität und gesichertes Wissen steht. Das umfangreiche CME-Angebot und die gezielte Berichterstattung für alle Fachgebiete unterstützen den Arbeitsalltag.



Mit unserem Newsletter erhalten Sie Fachinformationen direkt in Ihr Postfach – wöchentlich und kostenlos.